Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis

improved, unchanged and worsened by 64.3%, 21.4% and 14.3%, respectively. The EDSS for a 0.5 point sustained (no change over 3 months) effect was improved, unchanged and worsened by 42.9%, 42.9% and 14.2%, respectively. The EDSS for a 1.0 sustained effect was improved, unchanged and worsened by 28.6%, 57.1% and 14.3%, respectively.

Brian Loftus, M.D. of Bellaire Neurology, the Principal Investigator of these Tovaxin studies, commented, "This data, combined with prior data presented on myelin reactive T-cell frequencies and ARR reductions, laid the ground work for the placebo-controlled Tovaxin IIb clinical trial (TERMS). We have shown that myelin reactive T-cells can be identified and used to produce T-cell vaccine which effectively induces the depletion of an individual's autoreactive T-cells and results in positive clinical outcomes. I anticipate Tovaxin will usher in the age of personalized therapy for MS."

David McWilliams, president and chief executive officer of Opexa, said, "We are particularly encouraged by the data from this extension trial which indicates that subjects previously treated with T-cell vaccine can be safely and effectively retreated with Tovaxin. This outcome is important to our planned extension trial for subjects currently enrolled in our TERMS trial following the one year core study time period." In addition, the effectiveness data in RRMS subjects across the two Phase I/II trials indicate strongly positive outcomes in both ARR and EDSS improvements following Tovaxin therapy."

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T-cell vaccination with clinically isolated syndrome (CIS) and relapsing-remitting MS (RR-MS) patients. A total of 100 patients will receive Tovaxin, while 50 will receive placebo. The study is designed as a two-ar
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 26, 2011 Revenue of $374 million grew 5 ... share were $0.55 compared to $0.31 in the prior year, an increase of ... points to 13.3 percent Fiscal year 2011 ... 7 percent and earnings are expected to be $2.18 to $2.26 per diluted ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported ... 31, 2010. The Company reported total revenue of $174.2 ... net product sales of $162.3 million and revenue under ... $22.9 million for the quarter ended December 31, 2010, ...
Cached Medicine Technology:Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 2Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 3Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 4Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 5Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 6Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 7Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 8Amylin Pharmaceuticals Reports 2010 Financial Results 2Amylin Pharmaceuticals Reports 2010 Financial Results 3Amylin Pharmaceuticals Reports 2010 Financial Results 4Amylin Pharmaceuticals Reports 2010 Financial Results 5Amylin Pharmaceuticals Reports 2010 Financial Results 6Amylin Pharmaceuticals Reports 2010 Financial Results 7Amylin Pharmaceuticals Reports 2010 Financial Results 8Amylin Pharmaceuticals Reports 2010 Financial Results 9
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Grieving children from northern Allegheny, Armstrong, Beaver, Butler, ... to be served at new facility, PITTSBURGH, Feb. ... Children, Adolescents and Their Families, announced today its,intention to ... Cranberry,area, which will aim to serve children and families ...
... For years, getting a lot of,calcium has been ... do to,prevent osteoporosis and related bone fractures. Small study ... the data from,large, prospective studies that followed people for ... 2008 issue of the Harvard,Health Letter., The ambiguity ...
... Americans who,are unaware they have diabetes or are at ... Risk Test, ALEXANDRIA, Va., Feb. 25 The ... WHAT: The American Diabetes Association will "sound the alert" ... Tuesday, March 25,2008. American Diabetes Alert Day is a ...
... reducing cross contaminations including Influenza and ... ... today introduced,the new SILVER SEAL(TM) Washable, Antimicrobial Mouse at the HiMSS,Healthcare Symposium ... world,s first computer mouse to be fully submersible,dishwasher safe, and manufactured from ...
... With Standardized Pomegranate Extract and Pomegranate Seed Oil ... and Cell Protecting Benefits, EL SEGUNDO, Calif., ... use of,pomegranate in skincare for anti-inflammatory, antioxidant and ... equal; it is,the quality of the extract that ...
... AS PART OF ... SMART HEART CHALLENGE CAMPAIGN, CHICAGO, Feb. 25 Quaker ... hearts. Thanks to thousands of,Americans who signed up to take the ... King Cardiac Foundation (LKCF).,As part of this heart healthy campaign to ...
Cached Medicine News:Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 2Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 3Health News:High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter 2Health News:Sound the Alert!!! - March 25 is the 20th Annual American Diabetes Alert(R) Day 2Health News:Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 3Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 2Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 3
... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
... range of Platelet aggregometers allows to ... particular needs. Single, dual and four ... recorder outputs or digital computer outputs. ... aggregometers, which measure platelet aggregation in ...
... in achieving improved cost efficiency in ... cut costs is constantly increasing. Optimize ... unnecessary manual interactions. Ensuring security of ... mechanisms like pipetting integrity check. Right ...
... The Advia 2400 ... sample volume (as low ... water consumption (40 L/hour) ... The optional universal rack ...
Medicine Products: